In conclusion, these non-interventional studies in breast cancer patients treated with chemotherapy provide evidence that serum NfL has the potential to be used as a biomarker to monitor and mitigate CIPN, although studies with additional patients planned in the ongoing clinical trial will determine the universal application of NfL as a biomarker in CIPN. This evidence concerns the gene NEFL and breast carcinoma.